Internal Deadline: Friday, December 8, 2023, 5pm PT
LOI: January 10, 2024
External Deadline: February 9, 2024
Award Type: Cooperative Agreement
Estimated Number of Awards: 1
Anticipated Award Amount: $4,150,000
Who May Serve as PI: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Project Director/Principal Investigator (PD/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for HHS/CDC support.
Link to Award: https://www.grants.gov/search-results-detail/348751
Process for Limited Submissions
PIs must submit their application as a Limited Submission through the Research Initiatives and Infrastructure (RII) Application Portal: https://rii.usc.edu/oor-portal/. Use the template provided here: RII Limited Submission Applicant Template
Materials to submit include:
- (1) Two-Page Proposal Summary (1” margins; single-spaced; standard font type, e.g. Arial, Helvetica, Times New Roman, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 2-page limit will be excluded from review. You must use the template linked above.
- (2) CV – (5 pages maximum)
Note: The portal requires information about the PIs in addition to department and contact information, including the 10-digit USC ID#, Gender, and Ethnicity. Please have this material prepared before beginning this application.
The purpose of this research NOFO is to follow a cohort of interstitial cystitis (IC) patients over time, define the demographic and clinical patterns of IC, and document its impact on the health of affected people. In addition, the focus of this NOFO will include translating the scientific knowledge on IC extracted from previously funded and other studies so it can be used to support public health action, including patient strategies for improving quality of life, provider awareness and education, and medical and self-management of IC; strengthen clinical, community, and public health linkages; and target groups disproportionately impacted by IC.
The research objectives are to:
• Objective 1: Document the treatment (e.g., type) of people with IC
• Objective 2: Longitudinally follow patients with IC to determine the natural history (severity, progression, morbidity, mortality, etc.) of people with IC
• Objective 3: Examine potential disparities and other factors associated with IC by categories of interest (e.g., age, sex, race/ethnic group, geography (e.g., urban/rural), and socioeconomic status)
• Objective 4: Improve the surveillance case definition for IC by improving sensitivity and specificity.
• Objective 5: Improve diagnostic criteria for IC, and the ability to detect true cases.
• Objective 6: Improve understanding of the genetics of IC
• Objective 7: Translate the scientific knowledge on IC extracted from this study and others into tools and products that can be used to support public health action and provider awareness and education.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.